Pharmaceutical giants fined record €444 million for ‘abusive practices’
Share article:
Share article:

Pharmaceutical giants fined record €444 million for ‘abusive practices’

Credit: Belga

Three major pharmaceutical companies were imposed a record fine of €444 million by the French competition authority on Wednesday.

The companies – Novartis, Roche and Genentech – are accused of “abusive practices” to “preserve” sales of a drug treating macular degeneration (AMD) to the detriment of a cheaper competing treatment. AMD is an eye disease that leads to vision loss.

“Genentech, Novartis and Roche have implemented a set of behaviours (abuse of collective dominant position) aimed at preserving the position and price of Lucentis, by curbing the off-label use of the cancer drug Avastin,” the authority said.

Lucentis is a treatment for AMD, an age-related retinal disease, developed by Genentech (which has capital ties with the Roche and Novartis groups).

However, doctors realised that another Genentech drug, the anti-cancer drug Avastin, had positive effects on AMD and began prescribing it even though it does not have market authorisation for this disease.

Avastin costs 30 times less than Lucentis: an injection of Avastin costs €30 to €40, compared with €1,161 for Lucentis.

Novartis markets Lucentis worldwide outside the United States and Roche markets Avastin.

Novartis “sought to thwart the initiatives of ophthalmologists who, in the context of their freedom to prescribe, decided to prescribe Avastin, outside the scope of their market authorisation, in ophthalmology,” the competition authority said.

“Novartis, Roche and Genentech were also sanctioned for having implemented a series of blocking measures and for having disseminated an alarming, and sometimes misleading, message to the public authorities on the risks associated with the use of Avastin for the treatment of AMD,” it added.

The authority considers that “the practices in question are particularly serious, as they occurred in the health sector, where competition is limited, and more specifically, in a context of public debate on the impact on social finances of the extremely high price of Lucentis,” which has been reimbursed at 100%.

Novartis will be fined €385,103,250, while Roche and Genentech will have to pay €59,748,726, amounting to a grand total of €444,851,976.

“We are very disappointed by the outcome of the Decision of the French Competition Authority and strongly refute the accusations of the FCA regarding alleged anti-competitive practices,” a spokesperson for Novartis said.

“Novartis firmly believes the company has acted appropriately and in compliance with all applicable regulations. Novartis intends to appeal the FCA Decision before the Court of Appeal in France.”

“For the Belgian investigation Novartis provided full and transparent collaboration to the Belgian Competition Authority. We firmly believe that we acted appropriately and in compliance with all applicable regulations in Belgium,” the spokesperson said. “We remain committed to improving the health of patients, in accordance with high ethical business standards and in compliance with laws and regulations that govern the manufacture of medicines and their safe use in patients.”

The Brussels Times

This story has been updated to include comment from Novartis.

Latest news

Masks reintroduced indoors, teleworking encouraged
Masks will again be mandatory inside shops and other indoor public spaces, Prime Minister Alexander De Croo announced in a press conference on ...
Belgium intends to activate the pandemic law, says Health Minister
"We intend to activate the pandemic law," Public Health Minister Frank Vandenbroucke confirmed on Tuesday in the House committee, ahead of Tuesday's ...
Offers for fake Covid Safe Tickets circulating on social media
As the Covid Safe Ticket (CST) becomes mandatory in many places across Belgium, offers for forgeries are increasingly circulating on social media. ...
EU auditors: More worried about the future budget than about pervasive errors in the 2020 budget
The European Court of Auditors (ECA) have signed off the 2020 EU accounts as giving a true and fair view of the union’s financial position but like ...
Belgium aims to tackle sexual violence with video interrogations
The federal government is looking to tackle sexual violence and increase convictions connected to this crime by relying more heavily on video ...
Duvel celebrates 150th anniversary with special brew in commemorative bottle
Belgium’s Duvel Moortgat Brewery is celebrating its 150th anniversary with the release of a special brew in a commemorative bottle shaped like its ...
Pollution scandal: 3M to show emissions don’t pose risk or halt production
Flanders has ordered American company 3M, involved in a pollution scandal in Antwerp, to prove that emissions linked to its production activities do ...
The Netherlands fears a greater rise in sea levels than forecast
Sea levels could rise by up to two metres by 2100 on the Dutch coastline – far more than previously forecast – according to an announcement from the ...
The Smurfs return to Belgian TV with the first new show since 1989
A new Smurfs show is bringing the characters of Belgium's second-most-famous comic franchise back to the small screen with their first new series, 30 ...
On this day in Brussels: An entrepreneurial journey begins
The Rue Dansaert was just beginning to become trendy when Alain Coumont opened his first bakery here on 26 October 1990. He started by baking big ...
Almost half of Belgian subsidies from EU left unused
Belgium left almost half (49%) of its subsidies allocated by the European Union between 2013 and 2020 unused, the equivalent of around €1.375 ...
Visitors to embark on Orient Express adventure at Brussels exhibition
An exhibition dedicated to the Orient Express – the train that was the scene for many novels, including Agatha Christie's – allows visitors to ...